Madrigal Pharmaceuticals, Inc.

MDGL Healthcare Biotechnology

Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024. In the quarter to June 2026, revenue grew 71.2%, EPS fell 32.9%, free cash flow grew 140.5% and total debt rose 187.9%, each against the same quarter a year earlier.

449.74 10.07 −2.19%
Market cap
$10.6B
P/E
0.0×
Fwd P/E
−71.3×
Dividend yield
—
F-score
n/a
Altman Z
10.48
Beneish M
0.50
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
13.92 13.63 13.42 12.19
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
129.14 (97.89) (90.77) 670.81
P/B ratio
16.48 21.68 27.96 29.88
EV/Sales
12.88 12.95 13.00 11.80
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(57.61) (64.00) (53.41) (72.40)
Current Ratio
3.44 4.01 3.50 3.20
Net Debt/EBITDA
6.94 11.34 5.22 9.09
Debt/Equity
0.54 0.56 0.63 0.65
Earnings Yield
(2.59%) (2.02%) (2.37%) (2.40%)
Free Cash Flow Yield
(1.61%) (1.48%) (1.81%) (1.34%)
Free Cash Flow per Share
3.38 (5.93) (5.90) 0.65
Book value per Share
27.83 26.87 18.72 17.97
Free Cash Flow
75.99 (133.07) (171.28) 19.08
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates